Limits...
Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report.

Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, Panico L - Diagn Pathol (2012)

Bottom Line: Peripheral T-cell lymphomas not otherwise specified are generally considered aggressive non-Hodgkin lymphomas, because of poor natural outcome and response to therapy.They show a complex karyotype without any specific genetic hallmark.Several pitfalls could lead to misinterpretation of diagnosis, therefore, we underlined the need to integrate the classical histology and immunohistochemistry with molecular tests as clonality or fluorescence in situ hybridization.

View Article: PubMed Central - HTML - PubMed

Affiliation: Pathology Unit, National Cancer Institute Fondazione Giovanni Pascale, Via Mariano Semmola, 80131 Napoli, Italy.

ABSTRACT

Unlabelled: Peripheral T-cell lymphomas not otherwise specified are generally considered aggressive non-Hodgkin lymphomas, because of poor natural outcome and response to therapy. They show a complex karyotype without any specific genetic hallmark. We report a case of peripheral T-cell lymphoma not otherwise specified with heterogeneous nuclear cyclin D1 immunohistochemical overexpression, due to gene copy gain, a phenomenon similar to that observed in mantle cell lymphoma characterized by t(11;14)(q13;q32). In this case report we underline the diagnostic pitfall represented by cyclin D1 immunohistochemical overexpression in a T-cell lymphoma. Several pitfalls could lead to misinterpretation of diagnosis, therefore, we underlined the need to integrate the classical histology and immunohistochemistry with molecular tests as clonality or fluorescence in situ hybridization.

Virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1117747619703769.

Show MeSH

Related in: MedlinePlus

Illustration of Peripheral T cell lymphoma immunostaining. (A) Bcl6 immunonegativity 60X magnification. B) MIB1 strong nuclear immunopositivity in neoplastic T cells (40X). C) Cyclin D1 overexpression in neoplastic T cells (60X).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3475098&req=5

Figure 2: Illustration of Peripheral T cell lymphoma immunostaining. (A) Bcl6 immunonegativity 60X magnification. B) MIB1 strong nuclear immunopositivity in neoplastic T cells (40X). C) Cyclin D1 overexpression in neoplastic T cells (60X).

Mentions: Neoplastic cells show immunohistochemical positivity for T cell markers (CD2, CD3, CD5, CD43, CD4) and bcl2 (Figure1); B cell markers (CD20, CD79a and BSAP/Pax5) were expressed in residual follicles, in which a CD23 positive dendritc cells meshwork was occasionally observed (Figure1). The atypical cells were unreactive to CD10, CD8, CD56, CD57, CD1a, CD34, CD99 and ALK1. Only rare larger cells stained with CD30. The proliferation marker MIB1 was positive in almost 80% of cells. Unexpectedly cyclin D1 antibody was expressed by a cospicous part of the neoplastic T cells (Figure2).


Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report.

Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, Panico L - Diagn Pathol (2012)

Illustration of Peripheral T cell lymphoma immunostaining. (A) Bcl6 immunonegativity 60X magnification. B) MIB1 strong nuclear immunopositivity in neoplastic T cells (40X). C) Cyclin D1 overexpression in neoplastic T cells (60X).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3475098&req=5

Figure 2: Illustration of Peripheral T cell lymphoma immunostaining. (A) Bcl6 immunonegativity 60X magnification. B) MIB1 strong nuclear immunopositivity in neoplastic T cells (40X). C) Cyclin D1 overexpression in neoplastic T cells (60X).
Mentions: Neoplastic cells show immunohistochemical positivity for T cell markers (CD2, CD3, CD5, CD43, CD4) and bcl2 (Figure1); B cell markers (CD20, CD79a and BSAP/Pax5) were expressed in residual follicles, in which a CD23 positive dendritc cells meshwork was occasionally observed (Figure1). The atypical cells were unreactive to CD10, CD8, CD56, CD57, CD1a, CD34, CD99 and ALK1. Only rare larger cells stained with CD30. The proliferation marker MIB1 was positive in almost 80% of cells. Unexpectedly cyclin D1 antibody was expressed by a cospicous part of the neoplastic T cells (Figure2).

Bottom Line: Peripheral T-cell lymphomas not otherwise specified are generally considered aggressive non-Hodgkin lymphomas, because of poor natural outcome and response to therapy.They show a complex karyotype without any specific genetic hallmark.Several pitfalls could lead to misinterpretation of diagnosis, therefore, we underlined the need to integrate the classical histology and immunohistochemistry with molecular tests as clonality or fluorescence in situ hybridization.

View Article: PubMed Central - HTML - PubMed

Affiliation: Pathology Unit, National Cancer Institute Fondazione Giovanni Pascale, Via Mariano Semmola, 80131 Napoli, Italy.

ABSTRACT

Unlabelled: Peripheral T-cell lymphomas not otherwise specified are generally considered aggressive non-Hodgkin lymphomas, because of poor natural outcome and response to therapy. They show a complex karyotype without any specific genetic hallmark. We report a case of peripheral T-cell lymphoma not otherwise specified with heterogeneous nuclear cyclin D1 immunohistochemical overexpression, due to gene copy gain, a phenomenon similar to that observed in mantle cell lymphoma characterized by t(11;14)(q13;q32). In this case report we underline the diagnostic pitfall represented by cyclin D1 immunohistochemical overexpression in a T-cell lymphoma. Several pitfalls could lead to misinterpretation of diagnosis, therefore, we underlined the need to integrate the classical histology and immunohistochemistry with molecular tests as clonality or fluorescence in situ hybridization.

Virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1117747619703769.

Show MeSH
Related in: MedlinePlus